44th week of 2012 patent applcation highlights part 49 |
Patent application number | Title | Published |
20120277232 | Pyridine and Pyrazine Derivative for the Treatment of CF - The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed. | 2012-11-01 |
20120277233 | Pyridyl-Triazine Inhibitors of Hedgehog Signaling - The invention provides pyridyl-triazine derivatives to inhibit the hedgehog signaling pathway and the use of such compounds in the treatment of hyperproliferative diseases and angiogenisis mediated diseases. | 2012-11-01 |
20120277234 | 1,2,4-OXADIAZOLE BENZOIC ACIDS - Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. | 2012-11-01 |
20120277235 | Compositions For Topical Application Having Androgenic Actions - A composition comprising at least one physiologically tolerated film forming agent, at least one physiologically tolerated solvent, at least one plasticizer and a compound of the formula I | 2012-11-01 |
20120277236 | METHOD FOR INHIBITING MMP-9 DIMERIZATION - A method of inhibiting matrix metalloproteinase 9 (MMP-9) dimerization without substantially inhibiting the catalytic activity of MMP-9, comprising contacting the MMP-9 with a small molecule compound of the structure | 2012-11-01 |
20120277237 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of formula I wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. | 2012-11-01 |
20120277238 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE - The present invention provides a compound which indicates a histamine H4 receptor modulating activity. | 2012-11-01 |
20120277239 | Compositions and Methods for Improving Night Vision - The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 2012-11-01 |
20120277240 | SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES - The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2012-11-01 |
20120277241 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 2012-11-01 |
20120277242 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus - Provided are compounds of Formula (I): wherein R | 2012-11-01 |
20120277243 | PYRAZOLIDIN-3-ONE DERIVATIVES - The present invention relates to ethynyl derivatives of formula I | 2012-11-01 |
20120277244 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them. | 2012-11-01 |
20120277245 | Method of Increasing Intratumoral pHe and Reducing Acid-Mediated Invasion - A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO | 2012-11-01 |
20120277246 | Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders - Use of the N-phenyl-2-pyrimidine-amine derivatives of formula I, | 2012-11-01 |
20120277247 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. | 2012-11-01 |
20120277248 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS - Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer. | 2012-11-01 |
20120277249 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME - There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases. | 2012-11-01 |
20120277250 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention relates to compounds of formula I: | 2012-11-01 |
20120277251 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE - Compounds represented by the following structure (II) are disclosed: | 2012-11-01 |
20120277252 | Antibacterial Agents and Methods of Use Thereof - The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial compounds in wide use. For example, the present invention provides chalcone and cyanopyridine compounds, and derivatives thereof, exhibiting high antibacterial activities having multiple electron withdrawing group substituents, such as halogens and fluorinated alkyl groups, and optionally having hydroxyl and/or alkoxyl groups substituents. | 2012-11-01 |
20120277253 | SUBCUTANEOUS PALIPERIDONE COMPOSITION - The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a pharmacokinetic profile in vivo with substantially no burst release of the paliperidone. The compositions are useful as medicaments for the treatment of psychotic disorders and diseases. | 2012-11-01 |
20120277254 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2012-11-01 |
20120277255 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2012-11-01 |
20120277256 | FREQUENCY MODULATED DRUG DELIVERY (FMDD) - Embodiments of the present disclosure include a coordination complex, comprising a first biologically active moiety, a second biologically active moiety, and a metal, wherein the first biologically active moiety and second biologically active moiety are bound to the metal by covalent coordination bonds, and wherein the first biologically active moiety and second biologically active moiety are different. These complexes may enhance the pharmacodynamic properties of biologically active moieties. | 2012-11-01 |
20120277257 | Methods of Treating Diseases, Pharmaceutical Compositions, and Pharmaceutical Dosage Forms - Disclosed herein are methods of treating diseases and disorders responsive to inhibition of Hsp90, pharmaceutical compositions, pharmaceutical dosage forms and medicaments useful for the treatment of diseases responsive to inhibition of Hsp90, and methods of making the pharmaceutical compositions, pharmaceutical dosage forms and medicaments. | 2012-11-01 |
20120277258 | Chemical Compounds - Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. | 2012-11-01 |
20120277259 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS - The present invention relates to substituted benzofused derivatives, which can be used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them. | 2012-11-01 |
20120277261 | PHARMACEUTICAL FORMULATIONS USEFUL IN THE TREATMENT OF INSOMNIA - There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles. | 2012-11-01 |
20120277262 | NEW AMINOTETRALINE DERIVATIVES - The present application relates to compounds of formula (I): and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medicaments for the treatment of various diseases and conditions, such as of the central nervous system. | 2012-11-01 |
20120277263 | POLYMORPHS OF 1-CYCLOPROPYL-7-([S,S])-2,8-DIAZADICYCLO[4.3.0]NON-8-YL)-6-FLUORO-1,4-DIH- YDRO -8-METHOXY-4-OXO-3-QUINOLINE CARBOXYLIC ACID HYDROCHLORIDE AND METHODS FOR THE PREPARATION THEREOF - Two novel crystalline forms, designated form A and form B of the antibacterial agent 1-cyclopropyl-7-([S,S])-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride of formula, | 2012-11-01 |
20120277264 | ANTITHROMBOTIC AGENT - An object of the present invention is to provide an antithrombotic agent that has fewer side effects and that is highly effective. The present invention provides an antithrombotic agent comprising (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by Formula (1) as an active ingredient. | 2012-11-01 |
20120277265 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF - The invention relates to a method for chelating metal ion and/or dissolving amyloid aggregates, including chelating metal ions and/or dissolving amyloid aggregates with a compound of formula (I): | 2012-11-01 |
20120277266 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 2012-11-01 |
20120277267 | METHOD OF MANAGING OR TREATING PAIN - A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C | 2012-11-01 |
20120277268 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID - The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. | 2012-11-01 |
20120277269 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 2012-11-01 |
20120277270 | Method for Decreasing Symptoms of Alcohol Consumption - The present invention relates to methods and compositions of metadoxine and physiologically compatible active derivatives thereof, and their use for decreasing symptoms of alcohol consumption as well as in the prevention of alcohol consumption related symptoms in subjects in need thereof. | 2012-11-01 |
20120277271 | METHODS AND COMPOSITIONS - The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of nociceptive pain. More particularly, the present invention provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic or inflammatory pain. The present invention further contemplates combination therapy involved in the treatment of pain in association with the treatment of a particular disease condition or pathology. The present invention further also provides sustained and slow release formulations, tamper-proof deliver systems and stents, catheters and other mechanical devices coated with formulations which permit sustained or slow release of active ingredients involved in pain management. | 2012-11-01 |
20120277272 | Ethanamine Compounds and Methods of Using the Same - (S)-2-methyl- | 2012-11-01 |
20120277273 | SMALL MOLECULE INHIBITORS OF RGS PROTEINS - The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases). | 2012-11-01 |
20120277274 | EPOTHILONE COMPOUND FORMULATIONS - The present application relates to compositions for parenteral administration of epothilone compounds, such as ixabepilone. | 2012-11-01 |
20120277275 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE - Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: | 2012-11-01 |
20120277276 | TREATMENT OF EDIBLE CROPS - In the growing of crops for consumption, a method for the removal of pathogens includes the addition to irrigation water for the crops of an anti-pathogen composition and supplying the anti-pathogen composition to the crops prior to harvest while normal irrigation is effected. The anti-pathogen composition is based on halogens, such as chlorine, bromine and iodine, or mixtures of halogens or halogens combined with other organic radicals including cyanurate, hydantoin, peroxide and chlorine dioxide. BCDMH and TICA are preferred anti-pathogen components of the anti-pathogen composition and may be added to a carrier concentrate and measured and dosed into the irrigation water. | 2012-11-01 |
20120277277 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal - Disclosed are methods for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals, comprising administering to a mammal in heed thereof a pharmaceutical composition comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-tumour agent or in combination with radiation therapy. | 2012-11-01 |
20120277278 | PHENYLBUTAZONE CARRIER FORMULATION SHOWING INCREASED BIOACTIVITY IN ANIMALS - An improved phenylbutazone carrier composition provides increased palatability to horses. Additionally, the composition improves the bioavailability of the phenylbutazone and thus increases the horse's blood plasma levels of the medicine for the same effective dosage of the medicine. | 2012-11-01 |
20120277279 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions - The present invention provides compounds of formula (I): | 2012-11-01 |
20120277280 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS - The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound. | 2012-11-01 |
20120277281 | POLYNUCLEOTIDES FOR MEDICAL USE - The invention pertains to a RNA molecule transcribed form a long terminal repeat (LTR) sequence, comprising
| 2012-11-01 |
20120277282 | POLYNUCLEOTIDES FOR USE IN MEDICINE - The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above | 2012-11-01 |
20120277283 | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications - The present invention is directed to compositions and methods of localized delivery of a functionalized nanoparticle. | 2012-11-01 |
20120277284 | MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3)EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases. | 2012-11-01 |
20120277285 | CONTROL OF GENE EXPRESSION - The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided. | 2012-11-01 |
20120277286 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF MITOCHONDRIAL DISEASES - The present invention features compositions and methods for the treatment or prevention of diseases associated with a mitochondrial defect. | 2012-11-01 |
20120277287 | Modulating the CDC14B-CDH1-PLK1 Axis and Methods for Sensitizing Target Cells to Apoptosis - The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating Plk1 levels, and in particular to increasing Plk1 levels, to sensitize target cells such as cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to inhibitors of Cdc14B and Cdh1 that sensitize tumor cells to chemotherapy or radiation induced cell death or apoptosis. In addition to applications relating to cancer therapies and diagnostics, the Plk1 modulators and assays will be employed for identifying novel drugs or drug candidates useful for various proliferative and/or differentiative disorders such as major opportunistic infections, immune disorders, cardiovascular diseases and inflammatory disorders. | 2012-11-01 |
20120277288 | Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification - Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method. In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed. | 2012-11-01 |
20120277289 | ACTIVITY GENERATING DELIVERY MOLECULES - Activity-generating delivery molecules comprising the structure R | 2012-11-01 |
20120277291 | PREVENTIVE FOR ADHESION FOLLOWING ABDOMINAL SURGERY - The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions. | 2012-11-01 |
20120277292 | ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF - Antisense oligonucleotides against cPLA | 2012-11-01 |
20120277293 | Immunostimulatory Method - Methods for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition who does not respond or responds poorly or inadequately to steroid anti-inflammatory treatment or a steroid dependent patient afflicted with an inflammatory condition and currently on steroid anti-inflammatory treatment who shows an inability to be weaned off systemic or topical administered steroid treatment comprise administering an oligonucleotide having the sequence 5′-X | 2012-11-01 |
20120277294 | FUNCTIONAL FOOD ADDITIVES - Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases. | 2012-11-01 |
20120277295 | KIT FOR CANCER TREATMENT AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT - To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever. | 2012-11-01 |
20120277296 | Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease - The present invention relates to selective CB2 agonists for use in the prevention or treatment of alcoholic liver disease and particularly alcoholic hepatic steatosis and liver inflammation, and pharmaceutical composition thereof. | 2012-11-01 |
20120277297 | Pharmaceutical Composition Useful as Acetylcholinesterase Inhibitors - The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marrnesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7 -methoxycoumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions possess a high degree of acetylcholinesterase inhibitory (AChE) property. | 2012-11-01 |
20120277298 | FLAVANONES-CONTAINING FOOD COMPOSITIONS - The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of compositions for the improvement of bone and skin health. | 2012-11-01 |
20120277299 | METHOD FOR MODULATING ION TRANSPORTER - The present invention relates to a method for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising an administration at a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising a fatty acid derivative. | 2012-11-01 |
20120277300 | COMPOSITIONS AND METHODS FOR INDUCING BONE GROWTH AND INHIBITING BONE LOSS - Compositions useful for inducing bone growth or inhibiting bone loss in an animal comprising one or more isoflavones or isoflavone metabolites and methods for inducing bone growth or inhibiting bone loss in an animal utilizing such compositions. The compositions and methods are particularly useful for post-menopause, post-andropause, gonadectomized, spayed, or neutered animals. | 2012-11-01 |
20120277301 | CHROMAN-DERIVED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN MEDIATED DISORDERS - Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer. | 2012-11-01 |
20120277302 | EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 2012-11-01 |
20120277303 | EQUOL-CONTAINING FERMENTATION PRODUCT OF SOYBEAN EMBRYONIC AXIS, AND METHOD FOR PRODUCTION THEREOF - An object of the invention is to provide an equol-containing fermented soybean hypocotyl material that is useful for foods, pharmaceutical preparations, cosmetic products, etc. | 2012-11-01 |
20120277304 | SODIUM TRANSHINONE IIA SULFONATE HYDRATE AND PREPARATION METHOD AND USE THEREOF - The present invention relates to sodium tanshinone IIA sulfonate hydrates as well as preparation methods and uses thereof. The sodium tanshinone IIA sulfonate hydrates have molecular formula of C | 2012-11-01 |
20120277305 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES - The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative. | 2012-11-01 |
20120277306 | COMPOSITION CONTAINING METAL-ACIDIC AMINO ACID CHELATE ACCELERATING ABSORPTION OF METAL - Provided is a method for treating prostate and/or testicular disease, comprising: administering a pharmaceutical composition comprising a zinc-aspartate chelate as an active ingredient to a subject in need thereof, wherein the prostate disease is selected from the group consisting of prostatitis, enlargement of prostate and prostate cancer. The composition for accelerating absorption of metals, comprising a metal-acidic amino acid chelate as an active ingredient. The composition of the present invention has therapeutic effects on prevention and treatment of various diseases arising from a deficiency or shortage of metals, by utilization of a metal-acidic amino acid chelate that exhibits excellent effects of improving delivery and absorption of a drug into target organs, such that pharmaceutical effects of individual metals can be exerted. In particular, a pharmaceutical composition comprising a zinc-aspartate chelate increasing an intraprostatic zinc content as an active ingredient is highly effective for prevention and treatment of prostate and testicular diseases. | 2012-11-01 |
20120277307 | Method for Treating Osteoarthritis - A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed. | 2012-11-01 |
20120277308 | COMPOUNDS FOR TREATING CANCER AND OTHER DISEASES - This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases. | 2012-11-01 |
20120277309 | METHODS OF CONTROLLING VENOUS IRRITATION ASSOCIATED WITH THE TREATMENT OF A CARDIAC DISORDER - A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof. | 2012-11-01 |
20120277310 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one γ-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 2012-11-01 |
20120277311 | LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS - Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. | 2012-11-01 |
20120277312 | Ethylgallate and Related Compounds as a Treatment for Sepsis and Septic Shock - The use of ethyl gallate methyl gallate or 3,4-dihydroxybenzoate for treatment of septic shock Said compounds may also prophylactically treat septic shock via administration to a subject before the development of a fall in blood pressure. | 2012-11-01 |
20120277313 | COSMETIC COMPOSITION STABILIZED HIGHER OILY PART - The present invention relates to a cosmetic composition having a high content of a stable oil phase, and more particularly to a cosmetic composition, which combines advantages of spreadability and softness of an oil-in-water type with emollient effect and water resistance of a water-in-oil type as a resulting of stabilizing, based on the total weight of the composition, 30-56 wt % of an oily component by multiple emulsification of W/O/W, and which provides skin moisturizing and softening ef-fects by a large amount of oil components, and also which allows irritations caused by active ingredients to be relieved by a high content of the oily component. | 2012-11-01 |
20120277314 | CATHETER LOCK SOLUTION COMPRISING CITRATE AND A PARABEN - This invention relates to compositions, methods, devices and kits relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods, devices and kits aid in diminishing the effects of microbial infection in catheters and occlusion of the catheters. A lock solution provided by the invention includes citrate and a paraben. The solution preferably has a density suitable for retention of the solution in a catheter during the lock period. Another lock solution provided by the invention includes citrate, a paraben and a photo-oxidant, such as, for example, methylene blue. | 2012-11-01 |
20120277315 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS - A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer. | 2012-11-01 |
20120277316 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE - Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof. | 2012-11-01 |
20120277317 | USE OF A FATTY ACID COMPOSITION CONTAINING DHA FOR THE PRODUCTION OF A MEDICAL PRODUCT OR A FOOD STUFF FOR THE TREATMENT OF AMYLOIDOS-RELATED DISEASES - A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided. | 2012-11-01 |
20120277318 | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS FOR COUGH - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs. | 2012-11-01 |
20120277319 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 2012-11-01 |
20120277320 | INHIBITION OF THE SURVIVAL OF SKIN CANCER BY CYCLOHEXENONE COMPOUNDS FROM ANTRODIA CAMPHORATA - The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of | 2012-11-01 |
20120277321 | METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND BASED ON VANILLIN AND ETHYL VANILLIN, RESULTING COMPOSITION AND USES THEREOF - A method for preparing a composition including a compound based on vanillin and ethyl vanillin is described. A resulting composition and uses thereof in many fields of application, in particular in human and animal food is also described. A method for preparing a composition including a compound based on vanillin and ethylvanillin in a vanillin/ethyl vanillin molar ratio of 2 is also described wherein the method includes: a step of melting a mixture of vanillin and ethyl vanillin, which are used in a molar ratio other than 2, with an excess of vanillin representing from 2% to 20% of the weight of the mixture; a step of solidifying same, by cooling to a temperature of less than or equal to 50° C.±1° C.; and a step of recovering the resulting composition including the new compound. | 2012-11-01 |
20120277322 | Process for Bacterial Stabilizing of Aqueous Ground Natural Calcium Carbonate and/or Precipitated Calcium Carbonate and/or Dolomite and/or Surface-Reacted Calcium Carbonate-Comprising Mineral Preparations - This invention discloses a process for stabilising an aqueous mineral preparation comprising a step of adding at least one aldehyde-containing and/or aldehyde-releasing and/or phenolic and/or isothiazoline biocide to said aqueous mineral preparation. | 2012-11-01 |
20120277323 | CELLULOSE CAPSULES AND METHODS FOR MAKING THEM - Disclosed are cellulose capsules, methods for preparing a cellulose capsule, and compositions comprising cellulose capsules, including sustained- or controlled-release dosage forms comprising cellulose capsules. | 2012-11-01 |
20120277324 | BETAINE ESTERS AND PROCESS FOR MAKING AND USING - A variety of betaine esters, including dial kylaminoalkyl cocoate betaines. These betaines were advantageously prepared in high yield and purity by a three-step chemoenzymatic process. These betaine esters have excellent surfactant properties. | 2012-11-01 |
20120277325 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN PERFUME COMPOSITIONS - The present invention relates to novel pyrimidine derivatives and their use in perfume compositions. The novel pyrimidine derivatives of the present invention are represented by the following formula: | 2012-11-01 |
20120277326 | BIOMARKERS OF CANCER - Methods for diagnosis and staging of ovarian cancer, based on relative immunoreactivity of different IgG subclasses of autoantibodies, autoantibodies to defined antigens, e.g., antigens with specific subcellular localization, are described. | 2012-11-01 |
20120277327 | PROCESS AND APPARATUS FOR REFORMING HYDROCARBONS - The invention relates to a process and apparatus for the production of synthesis gas from a hydrocarbon feedstock in a heat exchanger reformer, wherein a cooling medium is added to the heat exchange reformer. | 2012-11-01 |
20120277328 | Conversion of Carbon Containing Feedstock - This invention relates to a process for the conversion of carbon containing feedstock to a liquid chemical product, particularly a liquid fuel product, wherein carbon dioxide emissions are minimized. | 2012-11-01 |
20120277329 | Process and System for Converting Waste to Energy Without Burning - This invention relates to a power recovery process in waste steam/CO | 2012-11-01 |
20120277330 | PROCESS FOR PRODUCING TRANSPORTATION FUELS FROM SYNGAS - A process for producing transportation fuels, such as gasoline and diesel fuel, from syngas with a low H | 2012-11-01 |
20120277331 | Vessel For Containing Catalyst In A Tubular Reactor - A catalyst carrier for insertion in a radial tube reactor, said catalyst carrier comprising: an annular container for holding catalyst in use, said container having a perforated inner wall defining a tube, a perforated outer wall, a top surface closing the annular container and a bottom surface closing the annular container; a surface closing the bottom of said tube formed by the inner wall of the annular container; a skirt extending upwardly from the perforated outer wall of the annular container from a position at or near the bottom surface of said container to a position below the location of a seal; and a seal located at or near the top surface and extending from the container by a distance which extends beyond an outer surface of the skirt. | 2012-11-01 |
20120277332 | ORGANIC SUPERACID MONOMERS CONTAINING A BIS-SULFONIC ACID GROUP AND METHODS OF MAKING AND USING THE SAME - One embodiment includes methods of adding two sulfonic acid groups to molecules having at least two cyclic groups. | 2012-11-01 |
20120277333 | STABILIZED AQUEOUS COMPOSITIONS COMPRISING CATIONIC POLYMERS THAT DELIVER PAINT AND PRIMER PROPERTIES IN A COATING - The present invention provides one component aqueous compositions comprising (i) a cationic stain blocking polymer chosen from (a) 0.01 to 7 wt. % of anion exchange resin copolymer gelular or dual morphology beads that have a weight average particle size of from 0.1 to 20 μm and a low copolymerized crosslinker content of from 0.5 to 2.0 wt. %, (b) from 1 to 30 wt. % a crosslinked cationic addition polymer and (c) mixtures thereof, (ii) one or more emulsion copolymer having a copolymerized residue of at least one phosphorus acid monomer, and (iii) a stabilizer of from 0.1 to 2 wt. % of an inorganic phosphorus containing dispersant, and from 0.2 to 5.0 wt. % of a mixture of a nonionic surfactant and an anionic surfactant, both wt. % s based on the total weight of emulsion compolymer solids. The compositions provide stabilized binders for in a single coat primer plus topcoat coatings and paints. | 2012-11-01 |